Jonathan E. Rosenberg
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
Papers in
- Co-authors
- Joaquim Bellmunt (45 shared papers)Eric Jay Small (20 shared papers)Toni K. Choueiri (27 shared papers)Daniel Peter Petrylak (25 shared papers)Brian I. Rini (7 shared papers)Guru P. Sonpavde (23 shared papers)Walter Michael Stadler (4 shared papers)Dean F. Bajorin (50 shared papers)
- Journals
- Annals of Oncology (30 papers)Journal of Clinical Oncology (28 papers)Clinical Genitourinary Cancer (20 papers)European Urology (19 papers)Cancer (15 papers)
- Partner nations
- United StatesItalySpain
In The Last Decade
Jonathan E. Rosenberg
294 papers receiving 35.6k citations
Jonathan E. Rosenberg's Hit Papers
Peers
Comparison fields: 5 of 145
- Oncology 13.5k
- Cancer Research 4.8k
- Surgery 14.1k
- Pulmonary and Respiratory Medicine 8.1k
- Immunology 4.5k
Countries citing papers authored by Jonathan E. Rosenberg
This map shows the geographic impact of Jonathan E. Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan E. Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan E. Rosenberg more than expected).
Fields of papers citing papers by Jonathan E. Rosenberg
This network shows the impact of papers produced by Jonathan E. Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan E. Rosenberg. The network helps show where Jonathan E. Rosenberg may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan E. Rosenberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 304 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Hit paper breakdown → | 2018 | 4038 |
| 2 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2016 | 3043 |
| 3 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types Hit paper breakdown → | 2019 | 3019 |
| 4 | Comprehensive molecular characterization of urothelial bladder carcinoma Hit paper breakdown → | 2014 | 2419 |
| 5 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2016 | 1811 |
| 6 | Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy Hit paper breakdown → | 2016 | 938 |
| 7 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Hit paper breakdown → | 2021 | 876 |
| 8 | Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Hit paper breakdown → | 2008 | 753 |
| 9 | Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Hit paper breakdown → | 2017 | 724 |
| 10 | Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206 Hit paper breakdown → | 2010 | 645 |
| 11 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Hit paper breakdown → | 2016 | 569 |
| 12 | Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy Hit paper breakdown → | 2019 | 520 |
| 13 | Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma Hit paper breakdown → | 2014 | 504 |
| 14 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients Hit paper breakdown → | 2022 | 418 |
| 15 | Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma Hit paper breakdown → | 2012 | 398 |
| 16 | 2010 | 368 | |
| 17 | A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Hit paper breakdown → | 2013 | 356 |
| 18 | 2008 | 340 | |
| 19 | High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade Hit paper breakdown → | 2020 | 339 |
| 20 | 2010 | 337 |
About Jonathan E. Rosenberg
Jonathan E. Rosenberg is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology, having authored 304 papers that have together received 36.2k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (204 papers), Urinary and Genital Oncology Studies (75 papers), Cancer Immunotherapy and Biomarkers (42 papers), Renal cell carcinoma treatment (22 papers), Epigenetics and DNA Methylation (19 papers), Cancer Genomics and Diagnostics (15 papers), Prostate Cancer Treatment and Research (12 papers) and Esophageal Cancer Research and Treatment (9 papers). The work is most often cited by research in Oncology (13.5k citations), Cancer Research (4.8k citations), Surgery (14.1k citations), Pulmonary and Respiratory Medicine (8.1k citations) and Immunology (4.5k citations). Jonathan E. Rosenberg has collaborated with scholars based in United States, Italy and Spain. Frequent co-authors include Joaquim Bellmunt, Eric Jay Small, Toni K. Choueiri, Daniel Peter Petrylak, Brian I. Rini, Guru P. Sonpavde, Walter Michael Stadler, Dean F. Bajorin, Elisabeth I. Heath and Bernard H. Bochner. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Genitourinary Cancer, European Urology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.